【突发】GSK 疫苗意外发现抗痴呆潜力！现实世界实验引爆学界震动
导语： 在阿尔茨海默病治疗遭遇瓶颈的当下，一款已上市的带状疱疹疫苗正引发科学界的新期待。英国制药巨头葛兰素史克（GSK）宣布与英国痴呆研究所（UK DRI）合作，利用 NHS 接种政策调整形成的 “自然实验”，研究其明星疫苗 Shingrix ...
赛诺菲挖角 GSK 研发大将 加速创新管线布局
导语： 2025 年 3 月，赛诺菲宣布任命葛兰素史克（GSK）前全球研发负责人 Chris Corsico 为新任研发总监，旨在强化其在基因治疗、肿瘤免疫等领域的创新竞争力。这一人事变动正值赛诺菲面临专利悬崖与管线压力的关键期，而 GSK ...
腾讯网8 天
适应症有望扩大？葛兰素史克(GSK.US)正研究带状疱疹疫苗Shingrix能否 ...
智通财经APP获悉，葛兰素史克(GSK.US)正在英国对一大群老年人进行研究，以确定其畅销的带状疱疹疫苗Shingrix是否能降低患痴呆症的风险。这可能为 ...
BioSpace7 天
GSK Builds on Real-World Experiment to Study Shingrix’s Impact on Dementia
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...
证券之星8 天
适应症有望扩大？葛兰素史克(GSK.US)正研究带状疱疹疫苗Shingrix能否 ...
（原标题：适应症有望扩大？葛兰素史克(GSK.US)正研究带状疱疹疫苗Shingrix能否降低痴呆风险） 智通财经APP获悉，葛兰素史克(GSK.US)正在英国对一大群 ...
Pharmaceutical Technology on MSN7 天
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).
Fierce Biotech8 天
GSK takes advantage of natural experiment to study whether shingles vaccine can reduce ...
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...
Endpoints News8 天
GSK to re­search whether shin­gles vac­cine can cut de­men­tia risk
GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...
美股异动 | 葛兰素史克盘前涨近2% 适应症或扩大 研究Shingrix能否降低 ...
格隆汇3月25日｜葛兰素史克 (GSK.US)盘前涨1.8%。消息上，葛兰素史克正在英国对一大群老年人进行研究，以确定其畅销的带状疱疹疫苗Shingrix是否能降低患痴呆症的风险。这可能为扩大该疫苗的适应症打开大门。据悉，该研究从2023年开始，为期四年，面向140万65岁至66岁的老年人，其中一些人接受了Shingrix疫苗注射，一些人则没有。一些研究已经表明，带状疱疹疫苗与降低患痴呆症风险有关 ...
MARKET WATCH: Could GSK jab lower risk of Dementia? Drugs giant to trial its shingles jab ...
GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...
GSK Studying If Blockbuster Shingles Shot Reduces Dementia Risk
GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...